These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23681135)

  • 1. Mesoglycan treatment in Raynaud phenomenon: a case series.
    Di Biase A
    Minerva Cardioangiol; 2013 Jun; 61(3):323-31. PubMed ID: 23681135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The usefulness of capillaroscopy for the evaluation of pulsed magnetic field therapy in patients with primary and secondary Raynaud's phenomenon].
    Kuryliszyn-Moskal A; Kita J; Dakowicz A; Klimiuk PA
    Ann Acad Med Stetin; 2011; 57(3):17-22; discussion 22. PubMed ID: 23383543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
    Shenoy PD; Kumar S; Jha LK; Choudhary SK; Singh U; Misra R; Agarwal V
    Rheumatology (Oxford); 2010 Dec; 49(12):2420-8. PubMed ID: 20837499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.
    Vayssairat M
    J Rheumatol; 1996 Nov; 23(11):1917-20. PubMed ID: 8923366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of mesoglycan in patients with previous deep venous thrombosis and chronic venous insufficiency.
    Andreozzi GM
    Minerva Cardioangiol; 2007 Dec; 55(6):741-53. PubMed ID: 18091643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Raynaud's phenomenon; diagnosis and treatment].
    Hofstee HM; Voskuyl AE; Serné EH; Smulders YM
    Ned Tijdschr Geneeskd; 2009; 153():B216. PubMed ID: 19785782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of the plethysmographic amplification factor during vasodilator treatment. Healthy subject versus primary Raynaud phenomenon].
    Lasfargues G; Royere D; Perrotin D; Titon JP; Soutif D; Guilmot JL
    J Mal Vasc; 1987; 12(4):319-22. PubMed ID: 3694055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microcirculatory changes in patients with primary Raynaud's phenomenon after treatment with buflomedil.
    Jacobs MJ; Lemmens HA
    Int J Microcirc Clin Exp; 1985; 4(1):63-8. PubMed ID: 3886577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CysLT1 receptor inhibition in patients with Raynaud's phenomenon: capillaroscopic evidence of the role of leukotriene.
    Azevedo MN; Bernardini EM; Salles EF; Heinzmann F; Marconde F; Mello T; Gomes BE
    Rev Bras Reumatol; 2012; 52(1):30-2. PubMed ID: 22286643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
    Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syncope and Raynaud's disease.
    Guiloff RJ; Rajakulendran S; Angus-Leppan H
    Arch Neurol; 2012 May; 69(5):608-13. PubMed ID: 22248476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.